Tirzepatide vs semaglutide in obesity; GLP1a use is complicated; HF outcomes; the misuse of meta-analyses in HF; and a breakthrough in HF care are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. SURMOUNT 5
- Clinicaltrials.gov https://clinicaltrials.gov/study/NCT05822830
- Press Release
-
II. Access to GLP-1 Agonist Drugs
- CMS statement https://www.cms.gov/newsroom/press-releases/biden-harris-administration-announces-medicare-advantage-and-medicare-part-d-prescription-drug
III. SUMMIT TRIAL commentary
Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?
https://www.medscape.com/viewarticle/has-tirzepatide-scaled-hfpef-obesity-summit-2024a1000m2h
IV. Blank Spot in HF Evidence – All cause hospitalizations
- Sayed and colleagues What Is Success in HF Trials? https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827168
- EMPEROR-Preserved https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
- Mayo Observational Study 10.1016/j.mayocp.2016.11.009
- DIG Trial https://jamanetwork.com/journals/jama/fullarticle/195990
V. Misuse of Meta-analysis by HF Community
- Lu and colleagues PARAGON/PARADIGM Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2823259
- Desai 2004 https://jamanetwork.com/journals/jama/fullarticle/199995
- PARADIGM HF https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
VI Integration of Palliative Care Into HF Care
- Chuzi and colleagues Palliative Care in HF 10.1016/j.cardfail.2024.10.435
- Kotecha and colleagues Beta-blocker Metaanalysis 10.1016/S0140-6736(14)61373-8
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
